Pulmonary edema refers to the buildup of excess fluid in the air sacs (alveoli) of the lungs. The condition can result from congestive heart failure, acute lung injury, acidosis, kidney failure and may require treatments like diuretics, vasodilators, oxygen therapy and more. The global pulmonary edema therapeutics market has grown significantly over the past few years on account of the rising prevalence of various cardiac and pulmonary disorders worldwide. Conditions such as chronic obstructive pulmonary disease (COPD), asthma, pneumonia are increasingly common and tend to worsen pulmonary edema in severe cases. The availability of various drug classes such as ACE inhibitors, angiotensin II receptor blockers and B-blockers have also augmented market growth as effective management of pulmonary edema symptoms is necessary to prevent respiratory failure.
The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: One of the key trends in the pulmonary edema therapeutics market is the increasing R&D in novel drug delivery mechanisms. Pulmonary route of drug administration is gaining significance as it allows for direct delivery of drugs to the lungs, bypassing first-pass metabolism in the liver and resulting in better bioavailability. Companies are developing various types of inhalers, nebulizers and even stem cell therapies to more effectively manage pulmonary edema. Smart nebulizers connected to apps are also being researched to monitor medication adherence and dosage. Such innovations aim to improve treatment outcomes for pulmonary edema patients.
Porter's Analysis
Threat of new entrants: Very low as this market requires high capital investment and stringent regulations.
Bargaining power of buyers: Moderate due to presence of several drug manufacturers.
Bargaining power of suppliers: Low as raw materials are available from different suppliers.
Threat of new substitutes: Low as there are limited substitutes for medications used in treatment of pulmonary edema.
Competitive rivalry: High due to presence of global and domestic players competing on basis of product quality, pricing and innovation.
Key Takeaways
The Global Pulmonary Edema Therapeutics Market Demand is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030.
The global Pulmonary Edema Therapeutics market is expected to witness high growth. North America region currently dominates the market owing to growing prevalence of cardiovascular and lung disorders and technological advancements. Europe is also expected to showcase substantial growth in the forecast period. As per American Lung Association, pulmonary edema causes nearly 150,000 deaths each year in United States alone. Europe is also estimated to witness notable growth in view of growing medical awareness and healthcare expenditure in countries like Germany, France and United Kingdom.
Key players operating in the Pulmonary Edema Therapeutics are Crayola LLC, Faber-Castell AG, Sargent Art, Reeves (Colart Group), Liquitex (Colart Group), Sax Arts & Crafts, Prang (Dixon Ticonderoga Company), RASCHER GmbH, Richeson Art Materials, Jovi S.L. Rising investments in R&D of novel drugs for treatment of pulmonary edema is enabling key players to expand their product portfolio.
For more details on the report, Read- https://www.insightprobing.com/pulmonary-edema-therapeutics-market-share-analysis/
Market HighlightsIncreasing prevalence of pulmonary edema and diseases like kidney failure, heart diseases, and others along with the growing geriatric population boosts the market growth.
On the other hand, low per capita healthcare expenditure in the middle and low-income countries, and lack of awareness about the disease are estimated to restrain the market growth.The global pulmonary edema market is expected to grow at an approximate CAGR of 7.2% during the forecast period.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/5607SegmentationThe global pulmonary edema market is segmented on the basis of type, diagnosis, treatment, and end user.
The blood tests segment is sub-segmented into b-type natriuretic peptide (BNP), blood count test, kidney function test, and others.
On the basis of the treatment, the market is segmented into preload reducers, morphine, suction catheter, and others.
The preload reducers segment is sub-segmented into nitroglycerin, diuretics, and others.
On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, retail pharmacies, and others.Regional AnalysisAmerica dominates the global pulmonary edema market due to the presence of a well-developed healthcare sector, high per capita healthcare expenditure and developed economies such as the U.S. and Canada within the region.
